The Japanese Ministry of Health, Labour and Welfare has approved Takeda Pharmaceutical‘s Orzeyful (oveporexton) for adults with type 1 narcolepsy (NT1). The approval follows a similar decision by the U.S. Food and Drug Administration…

In my experience, the people I meet in the narcolepsy community often become more than friends. They become like family. They are fellow warriors, advocates, and truth-tellers who challenge me to see my disease…

Takeda Pharmaceuticals’ Orzeyful (oveporexton) improved attention in people ages 16 to 65 with type 1 narcolepsy (NT1), with about six times the odds of achieving a clinically meaningful improvement compared with placebo, according…